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Abstract 
 
Estimating the reliability of individual predictions is key to increase the adoption of 
computational models and ‘artificial intelligence’ in preclinical drug discovery, as well as to foster 
its application to guide decision making in clinical settings. Among the large number of 
algorithms developed over the last decades to compute prediction errors, Conformal Prediction 
(CP) has gained increasing attention in the computational drug discovery community. A major 
reason for its recent popularity is the ease of interpretation of the computed prediction errors in 
both classification and regression tasks. For instance, at a confidence level of 90% the true 
value will be within the predicted confidence intervals in at least 90% of the cases. This so 
called validity of conformal predictors is guaranteed by the robust mathematical foundation 
underlying CP. The versatility of CP relies on its minimal computational footprint, as it can be 
easily coupled to any machine learning algorithm at little computational cost. In this review, we 
summarize underlying concepts and practical applications of CP with a particular focus on 
virtual screening and activity modelling, and list open source implementations of relevant 
software. Finally, we describe the current limitations in the field, and provide a perspective on 
future opportunities for CP in preclinical and clinical drug discovery. 
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Introduction 
 
A major research area in machine learning is the development of algorithms to compute the 
reliability of individual predictions. Such reliability estimates are essential to increase the trust 
and application of artificial intelligence solutions to guide decision making, especially in the 
context of healthcare and personalized medicine, where correctly identifying e.g., which patients 
are likely to benefit from a particular drug treatment has strong ethical and legal implications1.  
Estimating the reliability of predictive models is of particular relevance in drug discovery, where 
both the prediction and the associated uncertainty need to be taken into account for decision 
making2. The set of molecules for which a model is expected to generate reliable predictions is 
termed the applicability domain of a model3. Therefore, the development of algorithms to define 
and compute the applicability domain of predictive models has been an area of intense research 
in preclinical drug discovery, and due to the amount of recent research in the field we will in the 
following often focus on virtual screening in particular4–7. 
 
The generation of a predictive model, such as a Quantitative-Structure Activity Relationship 
(QSAR) model, or any other property model, consists of encoding the set of molecules for which 
the variable of interest has been experimentally measured (e.g., in vitro potency; the dependent 
or response variable) using numerical descriptors (covariates or independent variables)8–10. 
Subsequently, the covariates are related to the response variable using a mathematical model, 
which can be simple (e.g., multiple linear regression) or complex, such as Random Forests 
(RF), Support Vector Machines (SVM) or Deep Neural Networks, which might consist of 
thousands to millions of parameters11. These models are then used to predict the activity or 
property of interest for untested molecules in silico to prioritize for further experimental testing 
those with higher chances of being active. Although a plethora of algorithmically diverse 
approaches to encode chemical structures and to relate these to a dependent variable of 
interest have been developed over the last decades10,12, all depend on the limited amount of 
data available for training. This is key to drug discovery, as the amount and diversity of the 
training data (in this case chemical compounds) limits the set of small molecules to which a 
given model can be applied and give reasonable results. In practice usually more (and more 
homogenous) data is available in early-stage settings (such as hit discovery), and less so in 
later (such as in vivo) stages, making early stage model generation generally speaking relatively 
easier than late-stage models. However, what is generally applicable and a key question is how 
to assign the confidence, reliability, or applicability domain of a model, and while quantitatively 
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models in different stages might have larger or smaller applicability domains its importance is 
universal. 
 
Widely-used algorithms to generate QSAR models, such as Support Vector Machines (SVM) or 
Random Forest (RF), output a single value (regression) or label (classification) for new 
instances13–15. In practice, the lack of uncertainty estimates for point or single-class predictions 
hampers the use of computational models to guide prospective screening experiments in early-
stage drug discovery, given that ‘desired’ values of an output variable may well be associated 
with high uncertainty (and vice versa), but this will not be explicitly communicated to the user by 
the algorithm. However, in the same way experiments need to be repeated in order to assign 
both a measurement and its standard deviation of a variable, also computational predictions 
need to output the expectation value of the model and an associated confidence interval. 
 
We note that there exist algorithms whose outputs are well-calibrated probability distributions 
rather than point predictions, e.g., Gaussian Processes (GP)16–19 or Dropout Neural 
Networks20,21. However, these are generally computationally intense (e.g., GP training requires 
the inversion of the covariance matrix, which drastically increases their computational footprint), 
require the optimization of a large number of parameters, as well as prior knowledge about 
these19. Hence, most applications in the medicinal chemistry literature use alternative algorithms 
(e.g., RF), which are faster to train (by e.g., parallelizing the training phase), and require less 
parameter optimization22,23. Therefore, much effort has been invested in the community to 
develop uncertainty estimation methods that could be easily adapted to algorithms used in 
practice22,24–27.  
 
To date, a plethora of diverse algorithms have been developed to define the applicability domain 
of virtual screening models3,5,7,10,12,17,18,22,24,25,28–33. Overall, existing methods harness the 
distance in descriptor space of new instances to those in the training set 25,34, or intrinsic 
information derived from the models (e.g., bagged variance, which is positively correlated with 
high average error in prediction22,35), to identify areas in chemical space underrepresented in the 
training data for which the models are unlikely to deliver reliable predictions. The performance of 
these approaches is generally quantified by testing whether the error in prediction increases as 
a function of the distance of the test molecules to those in the training data34. However, such 
correlations do not guarantee that the predictions are well-calibrated, i.e., the fraction of 
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instances whose true value lies within the predicted error interval is not guaranteed to be 
proportional to a user-defined tolerated error rate. 
One method which has recently gained a lot of attention to address this problem is Conformal 
Prediction (CP; Table 1)36–38. CP is a mathematical framework to generate confidence predictors 
to model the reliability of predictions in diverse tasks, from property modelling to multi-target 
drug design (Table 2). A confidence predictor is a type of predictor that guarantees that the true 
value will be within the predicted confidence region (in regression) or within a set of predicted 
labels (in the case of classification) at a given confidence level (CL). For instance, at a 
confidence level of 80%, the confidence intervals computed using a valid Conformal Predictor in 
a regression setting would contain the true value in at least 80% of the cases (Figure 1a). In 
classification tasks, the set of predicted classes for new instances will contain the true label in at 
least 80% of the cases. The prediction of well-calibrated (or valid) confidence regions by CP, 
which is usually not the case for other modelling methods, guarantees a lower bound for 
validation rates, and permits to limit the number of false positives, thus increasing the retrieval 
rate of active compounds in preclinical drug discovery39. The confidence level is commonly set 
at 0.80, as this confidence level represents a generally suitable trade-off between efficiency and 
validity (note that a CL of 80% is also reported as 0.80 in the CP literature)40. The validity of CP 
holds if the randomness assumption is fulfilled, i.e., the training instances are representative of 
those to which the models will be applied; or, in other words, that the data are independent and 
identically distributed (i.i.d.). In practice, CP are also valid if the slightly weaker assumption of 
exchangeability is fulfilled, which assumes that the datapoints do not follow any particular order 
even if they are not i.i.d36,39. Although the exchangeability principle is generally assumed to hold 
when modelling preclinical data32,36,37, the authors have shown that this is not always the case in 
virtual iterative screening experiments using QSAR data sets (Figure 1b)41. Overall, CP does 
not introduce more assumptions than those generally made when modelling bioactivity data.  
To generate errors associated with predictions, Conformal Predictors evaluate the ‘non-
conformity’ of a new instance to those used during training by applying a new non-conformity 
measure. Intuitively, the non-conformity measure quantifies how different a given instance is 
from those already seen during the training phase, which is quantified using a non-conformity 
score (a). Therefore, any metric quantifying the applicability domain of a model, e.g., the 
distance of a new instance to the training set, can be used as non-conformity measure. The 
simplest non-conformity measure in a regression setting would be the unsigned error in 
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prediction computed for e.g., the instances or the hold-out folds in cross-validation. In 
classification tasks, non-conformity scores are generally computed using a class probability 
estimation method; for instance, the fraction of trees in a RF model voting for a particular class, 
the distance to the cut-off value or hyperplane that separates classes in the case of e.g., SVM 
(Table 2). Note that the selection of a non-conformity measure usually exploits information 
already provided by the underlying algorithm. For instance, in the case of RF models the 
fraction of Trees voting for each class in classification, of the bagged variance in regression, are 
often used as non-conformity measures.  
  
A second key aspect to consider is the efficiency of CP (Table 1). In regression, the efficiency of 
a Conformal Predictor is determined by the size of the predicted confidence regions. Even if a 
Conformal Predictor may be valid, it might not be useful in practice to guide decision making if 
the confidence regions span several bioactivity units40,42. In classification, efficiency is related to 
the fraction of single-class predictions that are correct38,43. 
 
In addition to the features listed above, Conformal Prediction can be used in combination with 
any machine learning algorithm32,37, requires minimal computational cost beyond the training of 
the underlying algorithm32, and no parameterization is required except for the selection of a non-
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Figure 1. (a) Example of a calibration plot for a well-calibrated Regression Conformal Predictor (adapted 
from 41). Calibration plots represent the fraction of confidence regions encompassing the true value (or, 1 
– estimated error rate) across increasingly larger confidence levels. The x-axis corresponds to a user-
defined confidence level, and the y-axis to the fraction of instances in the test set whose true value lies 
within the predicted confidence regions. It can be seen that the fraction of instances whose true value is 
within the predicted confidence interval (y-axis) is correlated with the confidence level, and hence this 
represents a ‘well-calibrated’ predictor in the context of Conformal Prediction, which can be used to 
assign the trust placed in future predictions of the model. (b) Example of a Regression Conformal 
Predictor that is not well-calibrated (adapted from 41). It can be seen that the fraction of instances whose 
true value is within the predicted confidence interval (y-axis) is not correlated with the confidence level. 
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conformity measure40. Hence, Conformal Prediction is a technique that permits to compute well-
calibrated and easy-to-interpret errors in prediction for both balanced and imbalanced data sets, 
as we discuss more in depth below, at minimal computational cost44.  
 
The first part of this review provides an overview of the design and advantages of the Conformal 
Prediction implementations used in drug discovery settings to date. The second part revisits the 
molecular modelling studies where Conformal Prediction played a key role in either estimating 
the reliability of individual predictions or in guiding prospective screening experiments. Finally, 
we discuss the current limitations of Conformal Prediction and offer a perspective on future 
directions. 
 
Table 1. Common terms used in Conformal Prediction. 
Term Definition 
Validity Conformal Predictors are always valid provided that the randomness or 
exchangeability principles hold. In the case of regression, a Conformal 
Predictor is valid if the confidence level matches the fraction of instances 
whose true value lies within the predicted confidence region. For instance, 
at a confidence level of 80%, the confidence intervals would contain the 
true value in at least 80% of the cases. In classification tasks, Conformal 
Predictors are valid in that the set of predicted classes for new instances 
will contain the true label in at least 80% of the cases. 
Efficiency In regression, the efficiency of a CP refers to the average size of the 
predicted confidence intervals. The tighter the intervals the more efficient a 
conformal predictor is. In the case of classification, efficiency refers to the 
fraction of single-class predictions that are correct. 
Confidence 
level (CL) 
The confidence level is defined by the modeler and refers to the minimum 
fraction of predictions whose true value will lie within the predicted 
confidence region, in the case of regression, and the fraction of instances 
whose true class will be among the set of predicted classes. 
Error rate The error rate refers to the fraction of instances whose true value lies 
outside the predicted confidence regions. If a CP is well-calibrated, the 
error rate should not be larger than 1-CL (see also Figure 1). 
Nonconformity 
measure 
Function used to evaluate the relatedness or conformity of new instances 
to those used for model training. 
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Table 2. Drug discovery studies listed in chronological order where Conformal Prediction was implemented. 
 
Data sets 
(targets; 
number of 
compounds; 
number of 
datapoints) 
Dependent 
variable or 
classes 
Machine 
learning 
technique 
Modelling 
type and task 
Type of 
Conformal 
Prediction 
used 
Prospectiv
e 
experiment
al 
validation? 
Reference Year Remarks 
10 publicly 
available data 
sets (Signature 
descriptors) 
pIC50 
Random 
Forest (RF) 
QSAR/Regres
sion and 
Classification 
Inductive 
Mondrian 
Conformal 
Prediction 
No Norinder et al.32  2014 
Introduction of Conformal 
Prediction in QSAR modelling 
12 human 
PARPs; 181 
compounds; 
2,164 
datapoints 
Thermal shift 
values measured 
using differential 
scanning 
fluorimetry45 
RF PCM/ Regression 
Inductive 
Conformal 
Prediction 
No 
Cortés-
Ciriano et 
al.46 
2015 Proteochemometric modelling (PCM) of PARP inhibition 
2 CAESAR 
binary 
classification 
datasets: 
carcinogenicity4
7 (805 
compounds) 
and 
mutagenicity48 
(4,204)  
Carcinogenic vs 
non-carcinogenic  RF 
QSAR/Classifi
cation 
Inductive 
Mondrian 
Conformal 
Prediction 
No Norinder et al.39 2015 
Modelling the carcinogenicity 
and mutagenicity of 
compounds using Mondrian 
Conformal Prediction 
Ames 
mutagenicity 
data set 
Non mutagenic 
vs mutagenic 
Support 
Vector 
Machines 
(SVM) 
QSAR/Classifi
cation 
Inductive 
Mondrian 
Conformal 
Prediction 
No Ahlberg et al.49  2015 
Interpretation of classification 
models 
NCI60 data set 
(59 cancer cell 
lines; 17,142 
compounds; 
941,831 
datapoints)  
pGI50 (50% 
growth inhibition 
bioassay end-
point) 
RF PCM/ Regression 
Inductive 
Conformal 
Prediction 
No 
Cortés-
Ciriano et 
al.50 
2016 
PCM of growth inhibition 
patterns across the NCI60 
data set. Webserver51 
available at 
www.cclp.marseille.inserm.fr 
2 datasets: 
Estrogen 
Receptor 
(binders/non-
binders: 
445/476) and 
Binders vs non-
binders (based 
on IC50 and 
relative binding 
affinity values) 
RF QSAR/Classification 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Norinder et al.54 2016 
Modelling compound binding 
to the estrogen and androgen 
receptors 
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Data sets 
(targets; 
number of 
compounds; 
number of 
datapoints) 
Dependent 
variable or 
classes 
Machine 
learning 
technique 
Modelling 
type and task 
Type of 
Conformal 
Prediction 
used 
Prospectiv
e 
experiment
al 
validation? 
Reference Year Remarks 
Androgen 
Receptor 
(binders/ non-
binders: 
292/633)52,53  
The Directory of 
Useful Decoys, 
Enhanced 
(DUD-E)55 
Actives vs 
inactives RF 
QSAR/Classifi
cation 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Svensson et al.56 2017 
Application of Conformal 
Prediction to guide docking 
experiments in an iterative 
fashion 
18 bioactivity 
data sets from 
the ExCAPE 
database8 
 
Actives vs 
inactives SVM 
QSAR/ 
Classification 
Mondrian 
Cross-
Conformal 
Predictors 
No Sun et al.57 2017 
Large-scale analysis of the 
application of Mondrian 
conformal predictors to model 
imbalance data sets with 
imbalance levels of 1:10 to 
1:1000. Non-conformity 
measure based on the SVM 
decision function 
3 datasets from 
PubChem 
(AID493091, 
AID2796 and 
AID1851) and 
Ames 
mutagenicity 
data set from 
Hansen et al.58 
Actives vs 
inactives SVM 
QSAR/Classifi
cation 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Norinder et al.59 2017 
Binary classification of 
imbalanced data using SVM 
and the distance to the 
separating hyperplane as the 
non-conformity measure 
Data set 
extracted from 
Baba et al.60 
encompassing 
211 compounds 
Permeation rate 
(log Kp) through 
the human skin 
RF and SVM Regression 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Lindh et al.61  2017 
Prediction of the permeation 
rate (log Kp) of chemical 
compounds through the 
human skin 
16 cytotoxicity 
datasets 
extracted from 
PubChem (data 
set size ranging 
from 29,938 to 
Toxic vs non-
toxic RF 
QSAR/Classifi
cation 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Svensson et al.62 2017 
Large scale modeling of 
cytotoxicity using largely 
imbalanced dataset (0.8% 
average fraction of toxic 
compounds) 
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Data sets 
(targets; 
number of 
compounds; 
number of 
datapoints) 
Dependent 
variable or 
classes 
Machine 
learning 
technique 
Modelling 
type and task 
Type of 
Conformal 
Prediction 
used 
Prospectiv
e 
experiment
al 
validation? 
Reference Year Remarks 
404,016 
compounds) 
25 protein 
targets from 
ChEMBL 
version 23 
pIC50 RF 
QSAR/Regres
sion 
Cross-
Conformal 
Prediction 
No 
Cortés-
Ciriano et 
al.41 
2018 
Demonstration that the 
exchangeability principle 
does not hold when 
conformal predictors trained 
on inactive molecules are 
applied generate CI for active 
molecules 
24 protein 
targets from 
ChEMBL 
version 23 
pIC50 
Fully-
connected 
deep neural 
networks 
QSAR/Regres
sion 
Deep 
Confidence No 
Cortés-
Ciriano et 
al.63 
2018 
Deep Confidence: Conformal 
Prediction strategy that used 
snapshot ensembles64 to 
generate conformal predictors 
for deep neural networks 
936 primary 
aromatic 
amines (630 
mutagenic and 
306 non-
mutagenic) 
Mutagenic vs 
non-mutagenic  RF 
QSAR/ 
Classification 
Inductive 
Mondrian 
Conformal 
Prediction 
No Norinder et al.65 2018 
Prediction of aromatic amine 
mutagenicity 
DGM/NIHS data 
set66 
encompassing 
12,140 
compounds 
categorized as: 
strong 
mutagenic, 
mutagenic and 
non-mutagenic. 
Strong 
mutagenic or 
mutagenic vs 
non-mutagenic 
RF QSAR/ Classification 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Norinder et al.67 2018 
Prediction of Ames 
mutagenicity 
316,974 from 
the PubChem 
BioAssay 
database (AID 
540275) 
Active vs 
inactive RF 
QSAR. 
Classification 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Norinder et al.68 2018 
Virtual screening of vanilloid 
receptor type 1 (TRPV1) 
agonists 
15,350 data 
points across 
31 
IC50, Ki, Kd, 
%inhibition and 
ΔTm 
RF, SVM and 
Generalized 
PCM. 
Classification 
Mondrian 
Cross- Yes 
Giblin et 
al.69 2018 
Application of PCM and CP to 
model the activity of 
compounds across 
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Data sets 
(targets; 
number of 
compounds; 
number of 
datapoints) 
Dependent 
variable or 
classes 
Machine 
learning 
technique 
Modelling 
type and task 
Type of 
Conformal 
Prediction 
used 
Prospectiv
e 
experiment
al 
validation? 
Reference Year Remarks 
bromodomain 
collected from 
ChEMBL 20, 
PubChem, 
ChEpiMod, 
GOSTAR, and 
proprietary 
AstraZeneca  
databases 
Linear Models 
(GLM) 
Conformal 
Predictors 
bromodomains. The model 
predictions for 1,139 
compounds were 
prospectively validated 
29 property, 
toxicity and 
bioactivity data 
sets from 
ChEMBL 
version 19 
pIC50, logS, 
Toxicity  
RF, Gradient 
Boosting 
Machines 
(GBM), Lasso, 
Ridge 
Regression, 
Bayesian 
Ridge 
Regression, 
Adaptive 
Boosting 
(AdaBoost), 
Automatic 
Relevance 
Determination 
(ARD), Elastic 
Net, and 
Partial Least-
Squares (PLS) 
QSAR and 
QSPR. 
Regression 
Inductive 
and 
Aggregated 
Conformal 
Prediction 
No Svensson et al.40 2018 
Benchmarking study of non-
conformity measures using 
QSAR data sets 
12 PubChem 
data sets (AIDs: 
411, 868, 1030, 
1460, 1721, 
2314, 2326, 
2451, 2551, 
485290, 
485314, 
504444) 
Actives vs 
inactives RF 
QSAR/Classifi
cation 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Svensson et al.70 2018 
Application of a gain-cost 
function including the 
screening cost and gain in 
terms of bioactivity 
information (e.g., discovery of 
a new hit) 
 12 
Data sets 
(targets; 
number of 
compounds; 
number of 
datapoints) 
Dependent 
variable or 
classes 
Machine 
learning 
technique 
Modelling 
type and task 
Type of 
Conformal 
Prediction 
used 
Prospectiv
e 
experiment
al 
validation? 
Reference Year Remarks 
108 
compounds71 
Skin sensitizers 
vs non-
sensitizers 
SVM QSAR/Classification 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Forreryd et al.72 2018 
Application of CP to model 
the readout of the Genomic 
Allergen Rapid Detection  
 Assay, used to test skin 
sensitizers 
ExCAPE 
database8 
 
Actives vs 
inactives SVM 
QSAR/Classifi
cation 
Aggregated 
Mondrian 
Conformal 
Prediction 
No Lampa et al.43 2018 
Prediction of off-target 
binding profiles across 31 
targets used in early hazard 
assessment 
8 toxicology 
data sets 
including off- 
target functional 
assays, 
cytotoxicity 
tests, 
mutagenicity 
tests, CYP450 
inhibition 
assays, acute 
oral toxicity 
assays and 
transporter 
assays 
extracted from 
the literature 
and public 
databases 
Actives vs 
inactives RF 
QSAR/Classifi
cation 
Inductive 
Mondrian 
Conformal 
Prediction 
No Ji et al.73 2018 
eMolTox: webserver for the 
prediction of compound 
toxicity 
1,592,127 
compounds 
from ChEMBL 
version 23 used 
for model 
development. 
The 
development 
model was 
applied to 
Compound 
lipophilicity 
(logD) 
SVM QSPR/Regression 
Cross-
Conformal 
Prediction 
No Lapins et al.74 2018 
Large-scale prediction of 
LogD. The logD prediction 
model is available as a REST 
service at 
https://cplogd.service.pharmb
.io/ 
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Data sets 
(targets; 
number of 
compounds; 
number of 
datapoints) 
Dependent 
variable or 
classes 
Machine 
learning 
technique 
Modelling 
type and task 
Type of 
Conformal 
Prediction 
used 
Prospectiv
e 
experiment
al 
validation? 
Reference Year Remarks 
91,498,351 
compounds 
extracted from 
PubChem 
database  
5 data sets from 
the UCI 
Machine 
Learning 
Repository75 
Two classes RF Binary classification 
Aggregated 
Mondrian 
Transductiv
e 
Conformal 
Prediction 
No Spjuth et al.76 2018 
Illustration of a novel 
framework (Non-Disclosed 
aggregated Conformal 
Prediction) to aggregate 
conformal predictors from 
multiple sources while 
keeping the data on which 
they trained private. High 
impact for drug discovery 
research 
MNIST dataset, 
and 3 drug 
discovery data 
sets measuring 
the Ames 
Mutagenicity, 
mitochondrial 
function, and 
interaction with 
the aryl 
hydrocarbon 
receptor of 
small molecules 
Two classes SVM+ QSAR/Classification 
Inductive 
Mondrian 
Conformal 
Prediction 
No Gauraha et al.77 2018 
Development of inductive 
conformal predictors using 
the Learning Under Privileged 
Information paradigm (LUPI) 
and SVM+ 
550 human 
protein targets 
from ChEMBL 
versions 23 and 
24 
pChEMBL RF QSAR/Classification 
Inductive 
Mondrian 
Conformal 
Prediction 
No Bosc et al.78 2019 
Large-scale comparison of 
QSAR and CP showed that, 
overall, CP outperforms 
QSAR, although for some 
targets the opposite was 
observed 
56,892 
compounds 
from 10 high-
throughput 
Active/Inactive 
Matrix 
Factorization 
(Macau) 
Multi-target 
binary 
classification 
Macau + 
Mondrian 
Aggregated 
No Norinder et al.80 2019 
Multitask learning using 
Conformal Prediction and 
matrix factorization 
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Data sets 
(targets; 
number of 
compounds; 
number of 
datapoints) 
Dependent 
variable or 
classes 
Machine 
learning 
technique 
Modelling 
type and task 
Type of 
Conformal 
Prediction 
used 
Prospectiv
e 
experiment
al 
validation? 
Reference Year Remarks 
screening data 
sets originating 
from 
PubChem79 
Conformal 
Prediction 
24 protein 
targets from 
ChEMBL 
version 23 
pIC50 
Fully-
connected 
deep neural 
networks 
Regression 
Test-Time 
Dropout 
Conformal 
Prediction 
No 
Cortés-
Ciriano et 
al.81 
2019 
First study integrating test-
time dropout and Conformal 
Prediction 
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Conformal Prediction Modalities Commonly Used in Computer-Aided Drug Design 
 
In this section, we will describe the most widely used Conformal Prediction modalities in the 
drug discovery literature, and the steps required to generate them (see a general pipeline 
below) using a real-world bioactivity data set. We refer the reader to the work of Vovk et 
al.32,36,37 for further details about the mathematical foundations underlying the Conformal 
Prediction framework, and to Norinder et al.32 and Eklund et al.44 for an introduction focused on 
the application of Conformal Prediction to virtual screening.  
The Conformal Prediction implementations we will discuss follow the same core steps, namely: 
1. Choosing a non-conformity measure to evaluate the non-conformity between the training 
and the test instances; 
2. Training the machine learning model of choice, and evaluate the non-conformity values 
for the training examples; 
3. Applying the trained model to the test or external set instances; 
4. For each test set instance, evaluating its non-conformity with respect to the training data 
using the same non-conformity measure used in step 1: the higher the conformity of the 
new instance, the higher the reliability of the prediction;  
5. Identifying reliable predictions given the user-defined significance and confidence levels; 
and 
6. Evaluating the validity and efficiency of the generated Conformal Predictor. 
 
Inductive Conformal Prediction (ICP) 
Inductive Conformal Prediction for Classification 
To generate an ICP model, the data available for training is divided into (see Figure 2) (i) a 
training set (also termed proper training set82), consisting of e.g., 70% of the data, (ii) a 
calibration set, encompassing e.g., 15% of the data, and (iii) a test set, consisting of the 
remaining datapoints. Both the proper training and calibration sets are used for training, 
whereas the test set is used to evaluate the predictive power of the models, as well as the 
validity and efficiency of the Conformal Predictors generated.  
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Figure 2. Steps for the generation of an Inductive Conformal Predictor in the context of classification. As in the main 
text, e denotes the significance level (Table 1). 
 
A machine learning model is firstly trained on the proper training set (step 1 in Figure 2), and 
subsequently applied to predict the activity label for the instances in the calibration set (step 2 in 
Figure 2; for illustration purposes, we here consider that the underlying model is always a RF 
model unless otherwise stated). The true and predicted class labels for the calibration set 
instances serve to compute non-conformity scores using the non-conformity measure of choice, 
for instance, the fraction of Trees from a Random Forest Model voting for the class receiving 
most votes. The non-conformity score serves to quantify the non-conformity (or ‘strangeness’) of 
a new instance with respect to those used for training. Predictions for which most of the Trees in 
the Random Forest predict the same label are more reliable, and hence, have a higher non-
conformity score than cases where the algorithm does not delineate both classes correctly; that 
is, both classes are predicted to be equally likely. The model is then applied to the test set and 
the fraction of Trees voting for the most voted class is recorded for each instance (step 3 in 
Figure 2). Finally, the P value for each test set instance is calculated as the fraction of instances 
in the calibration set with a non-conformity score equal or smaller than the nonconformity score 
for the instance under consideration. Thus, the P value represents the ranking of the non-
Train one machine 
learning model
Calibration set (15%) Test set (15%) Training set (70%)
Class predictions for 
the calibration set instances
(one class per instance)
Class predictions for the 
test set instances
(one class per instance)
Computation of P values 
for the test instances
2 3
1
Sort the list of 
nonconformity values
 (α)
4
Use P values to determine
the reliability of each prediction 
(i.e., reliable if P value >= ε)
Nonconformity values
0.51
0.67
0.75
0.78
0.86
0.89
0.91
0.95
0.98
0.99
Examples (confidence level 0.8; ε = 0.20)
- Unreliable prediction: 56% of the trees in the RF model 
vote for the active class (P = 1/10). 0.1 < ε
- Reliable prediction: 94% of the trees in the RF model
vote for the active class (P = 7/10). 0.7 > ε
Inductive Conformal Prediction Classification
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conformity score for a new instance with respect to the non-conformity score list generated for 
the calibration set. The P value is then compared against the significance level, e, which is 
defined as 1 – CL. A prediction is considered reliable if the P value is higher than e. Note that 
the concept of P value used here is not equivalent to traditional P values used in statistics. 
 
To illustrate this approach using real-world data, we collected pIC50 data for 5,207 compounds 
against the Human ether-a-go-go-related gene (hERG) potassium channel from the ChEMBL 
database version 239. To generate a RF binary classification model we considered as active 
those compounds with a pIC50 value ³ 7 (n=332), and assigned the remaining compounds to the 
inactive class (n=4,875). The resulting data set had an imbalance in the ratio of active to 
inactive compounds of ~1:15. This data set was previously used to benchmark bioactivity 
modelling pipelines83, and is publicly available at: 
https://github.com/isidroc/kekulescope/tree/master/datasets. Next, we calculated circular 
Morgan fingerprints for all compounds using RDkit (release version 2013.03.02) with a radius of 
2 and a fingerprint length of 1,024 bits. To generate an RF-based Inductive Conformal Predictor 
using a confidence level of 80% we followed the steps described in Figure 2, with the exception 
that 60% of the data was used as test set in this case for illustration purposes to ensure that we 
had enough active compounds to compute validity estimates for the resulting Conformal 
Predictors.  
We report in Figure 3 the distribution of non-conformity scores (a) for the calibration and (b) test 
sets. Unreliable predictions on the test set (shown in red in Figure 3b) are those whose non-
conformity value is smaller or equal than the 80th percentile of the list of non-conformity scores 
for the calibration set, indicated by the cross in Figure 3a, and by the black arrow in Figure 3a. 
As stated above, the mathematical validity of CP guarantees that at least 80% of the predictions 
considered reliable will be correct. However, the validity is only guaranteed globally, meaning 
that the error rate for the reliable predictions (i.e., fraction of predictions that are incorrect) might 
be different across classes, as some classes are harder to predict than others. This is a major 
issue when modelling imbalanced data, as the error rate will be higher for, usually, the minority 
class39. In fact, in the hERG data set modeled here we observe that most active compounds are 
predicted as unreliable (Figure 3c). Therefore, although 80% of the predictions flagged as 
reliable are correct (global validity), the percentage of active compounds with a reliable 
prediction is only 24% (28/115; Table 3 and Figure 3), and more importantly, only 14% of the 
active compounds with a reliable prediction are correctly predicted as active (Table 3). Thus, the 
local validity for the active class is not guaranteed. This behavior is understandable due to the 
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imbalance of the dataset used, which includes about 15 times more information about inactive 
compared to active compounds. Being aware of which predictions are more reliable than others 
now allows the modeler to proceed with those predictions with the desired confidence, e.g., for 
subsequent experimental compound testing. 
 
 Reliable predictions Unreliable predictions 
 Active Inactive Active Inactive 
Predicted Active 4 0 43 44 
Predicted Inactive 24 1,214 44 228 
Total 28 1,214 87 272 
 
Table 3. Confusion matrix for the classification model trained on the hERG data set, showing that the distribution of 
reliable and unreliable predictions across classes is not even, and in line with the data distribution in the training data 
set (which is biased towards the inactive class). The results correspond to the prediction for the test set molecules, 
and the reliability assignment now allows for the selection of molecules with the desired confidence for subsequent 
steps of e.g., experimental testing. See also Figure 3. 
 
Figure 3 Generation of an Inductive Conformal Predictor using the bioactivity data stored in ChEMBL version 23 for 
target hERG. The instances in the data set were assigned to the active or inactive class using a cut-off value of 7 
pIC50 units to generate a highly-imbalanced data set (active to inactive ratio of 1:15). (a) Non-conformity values for 
the instances in the calibration set. In this example the non-conformity function chosen corresponds to the fraction of 
Trees voting for the most voted class. For instance, if 85% of the trees in the RF model vote for the active class, the 
non-conformity score would be 0.85. The sorted list of non-conformity scores serves to calculate αCL. (b) The non-
conformity scores are calculated for each instance in the test set. Those predictions with α values equal or greater 
than αCL are considered reliable. In this case, unreliable predictions are those for which roughly the same number of 
Trees in the RF model vote for each class. In both (a) and (b) the instances in the x-axis have been sorted according 
to their non-conformity score (y-axis). (c) Distribution of inactive and active compounds in the set of reliable (left) and 
unreliable (right) predictions. The figure shows that most of the reliable predictions correspond to inactive 
compounds, which are easier to model given the imbalance in the data. Therefore, although at least 80% of the 
predictions considered reliable are correct, most of the active compounds are assigned an unreliable prediction 
(Table 3), allowing the modeler to focus on those predictions with the desired confidence in turn.  
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The lack of validity for each class (or local validity) fostered the development of Inductive 
Mondrian Conformal Prediction39,84, which permits to calibrate the error rates in a class-specific 
manner.  
 
Handling Imbalanced Datasets: Mondrian Conformal Prediction (MCP) 
 
In MCP each class (e.g., active and inactive) is treated separately, and the confidence in the 
assignment of a given instance to the classes considered is evaluated independently. That is, a 
list of non-conformity scores is generated for each class using the predictions for the calibration 
set (Figure 4). Thus, in a binary classification setting a compound might be classified as “active”, 
“inactive”, both active and inactive (class “both”), or not assigned to either of them (class “null” 
or “empty”).  
 
 
Figure 4. Steps required for the generation of a Mondrian Conformal Predictor.  
Specifically, the steps to generate an inductive MCP using a RF classification model are (Figure 
4): 
 
- Step 1. Training an RF model on the proper training set; 
 
Train one machine 
learning model
Calibration set (15%) Test set (15%) Training set (70%)
Class predictions for 
the calibration set instances
Class predictions for the 
test set instances
(one class per instance)
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for the test instances 
for each class
2 3
1
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4
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predicted to belong to both 
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- Fraction of tress voting for 
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- Step 2. Applying this model to classify the instances in the calibration set, and creating a 
list of non-conformity values (e.g., fraction of trees voting for that class in the case of RF) 
for each category (i.e., active and inactive in a binary classification setting). Next, sorting 
the lists of non-conformity values in increasing order, which are termed Mondrian class 
lists; 
 
- Step 3. Applying the model trained in step 1 to the test set, and for each instance 
compute the fraction of trees voting for each class; and 
 
- Step 4. For each instance in the test set computing a P value for each class. The P 
value is the fraction of cases in the corresponding Mondrian class list calculated using 
the calibration set predictions in Step 3 smaller than the vote fraction for that class. If the 
P value for a given class is above the significance level, ɛ, the test set instance under 
consideration is predicted to belong to that category. Compounds are assigned to all 
categories for which the P value is greater or equal than ɛ.  
 
Hence, a given compound may be predicted as “active”, “inactive”. However, it can also be 
predicted as “both” in cases when the model does not have enough predictive power to 
discriminate between classes, or “null” in cases when the instance is outside the applicability 
domain of the model. Thus, MCP gives an unbiased estimate of the reliability of the predictions 
given the training data on a class-specific manner. While this behavior might seem 
counterintuitive, it is actually a straightforward consequence of the types of data and evidence 
that might be present in a given training dataset – for example, if there are two closely related 
molecules to the one a prediction is made for, one of which is active and one of which is 
inactive, then there is evidence for both classes, and (at a given confidence level) none can be 
chosen over another. Likewise, if no evidence for either class is present in a data set (such as 
for a chemically very novel molecule), then no prediction either way can be made in practice. 
This aspect of modelling data is often neglected in other modelling approaches, which forces a 
decision onto the model, hence resulting in single labels which are often more easy to deal with 
in practice, but which neither consider the confidence of a prediction properly, nor the underlying 
evidence of class membership present in the available data. 
 
The significance level, ɛ, indicates the maximum fraction of predictions that are incorrect. In 
MCP this fraction is guaranteed for each class, which means that at least 1- ɛ of the predictions 
for the minority class will be correct. This is of utmost importance in drug discovery, where for 
example inactive molecules usually outnumber actives by several orders of magnitude. 
Likewise, for models in later stages of drug discovery, being able to anticipate for which areas of 
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chemical space no predictions can be made (and to assign a confidence to the remainder) is as 
important as being able to model the data in the first place.  
 
It is important to note that increasing the confidence level generally reduces efficiency, defined 
as the single-label prediction rate. In fact, the number of null class predictions is anticorrelated 
with the confidence level, whereas the number of predictions predicted to belong to both 
categories positively correlates with the significance level32. This relationship between 
confidence level and one-class assignments is illustrated in Figure 5, where we show the results 
generated using a MCP trained on the hERG data set described above (see also Table 4 and 
Figure 3). Hence in practice the modeler needs to make choices as to which confidence level 
and efficiency is desired in a particular case, which involves a certain amount of subjective 
choice as well. 
 
Since the introduction of MCP in the chemical-structure activity modelling community32, the 
advantages of MCP have been showcased in a number of applications, mostly to perform 
classification tasks using imbalanced data sets, which is the situation MCP sets out to address. 
Norinder et al.32 applied MCP to binary classification of compounds and showed that the 
number of null predictions and the confidence level are inversely correlated, whereas the 
opposite is observed for the both category (Figure 6). Therefore, increasing the confidence 
might lead to assign molecules to the both category that are already assigned only to the correct 
category at a lower confidence level, underlining that this parameter represents a trade-off 
between multiple factors, and that a higher confidence level is not always the better choice 
(Figure 6). By modelling Ames mutagenicity data using Mondrian ICP Norinder et al.6 showed 
that the inconsistency across data sets from different sources seems to prevent the generation 
of valid conformal predictors, likely in this case due to inconsistencies in categorizing 
moderately mutagenic compounds as mutagenic or non-mutagenic, which highlights the 
importance of evaluating data consistency prior to modelling85–87. This can also be seen as a 
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useful feature of CP algorithms, where the model itself is able to detect how consistent training 
data is which it is trained with, in the same way it is able to assign a confidence level to the 
output values. Norinder et al.4 also implemented Inductive MCP using Random Forest as the 
underlying algorithm to model the mutagenicity of 936 primary aromatic amines (630 mutagenic 
and 306 nonmutagenic) using Leadscope fingerprints88 where it was found that models were 
valid for both classes. A recent large-scale comparison of QSAR and MCP models for ligand-
target prediction using in vitro activity data for 550 human protein targets extracted from 
ChEMBL found that the predictive power of both approaches (in terms of correct classification 
rate) is overall similar for 92% of the targets considered at a confidence level of 80%78. The 
usefulness of MCP as a robust method to determine the applicability domain of predictive 
models for regulatory purposes has been shown by Norinder et al.39 using carcinogenicity and 
mutagenicity data. Overall, these studies showcase the versatility of MCP to handle imbalanced 
Figure 5. Modelling the hERG data set using Mondrian Conformal Prediction. (a) Fraction of trees voting for the active 
class for the active compounds in the calibration set. (b) Fraction of trees voting for the active class for the active 
compounds in the test set. Unreliable predictions (i.e., those with P values below the confidence level selected, 80%) 
are shown in red. (c) Distribution of class predictions for the active compounds in the test set. (d) Fraction of trees 
voting for the inactive class for the inactive compounds in the calibration set. (b) Fraction of trees voting for the 
inactive class for the inactive compounds in the test set. Unreliable predictions are shown in red. (c) Distribution of 
class predictions for the active compounds in the test set. It can be seen that the fraction of instances whose try value 
is among the set predicted labels is ~0.8 for both categories, which corrresponds to the selected confidence level in 
this case. The instances in a, b, d, and e have been sorted in increasing order according to the value of their 
associated non-conformity score (y-axis). 
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data sets. However, holding out the calibration set to generate the list of non-conformity scores 
hampers the use of all available labelled data for model training. Therefore, several flavours of 
CP designed to use all available data have been developed, which we will revisit later in this 
review (see section ‘Conformal Prediction Using All Labelled Data for Learning’). 
 
Table 4. Performance of the MCP model trained for the hERG data set. It can be seen that the predictions are 
globally and locally valid, i.e. across the model and also for individual classes. 
Confidence 
level 
Global 
validity 
Validity for 
actives 
Validity for 
inactives 
0.1 0.14 0.14 0.14 
0.5 0.5 0.41 0.51 
0.8 0.81 0.77 0.81 
0.9 0.92 0.9 0.92 
0.99 0.99 1 0.99 
 
ICP for Regression 
The underlying principles to generate Inductive Conformal Predictors for regression tasks are 
similar to those described above for classification models. Firstly, a model is trained on the 
proper training set (step 1 in Figure 7). Subsequently, the model is applied to the calibration set 
(step 2 in Figure 7). In the case RF-based ICP models the predicted value for each instance in 
the validation set,	"#, is then calculated as the average across the Trees in the Random Forest, 
and the standard deviation of these, $, is used as a measurement of the prediction’s 
uncertainty89. Scaling the absolute error in prediction using a measure of confidence about each 
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Figure 6. Influence of the confidence level on the efficiency of MCP classification models trained on the hERG data set 
and using increasingly larger confidence levels: 0.1 (a), 0.5 (b), 0.8 (c), 0.9 (d), and 0.99 (e). The numbers on top of the 
bars indicate the number of active compounds in each set. The x-axis indicates the predicted categories, whereas the 
colours indicate the true category for the compounds (i.e, active or inactive). It can be seen that the number of 
instances predicted to belong to both classes (category ‘both’) increases with the confidence level. 
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prediction (e.g., the bagged variance29) serves to generate tighter predictions for those 
prediction that are deemed more reliable90. Note that without this scaling all predictions for the 
new molecules would be of the same size (Equation 1). 
 
The residuals and the standard deviation across the forest are used to generate a list of non-
conformity scores for the calibration set as follows:  Equation	1:						 ∝0= 	 |"0 − "45|678  
where "0 is the ith instance in the validation set, and "45	and $0	are the average and the standard 
deviation of the predicted activities for the ith instance across the forest, respectively. The 
resulting list of non-conformity scores, 9, is sorted in increasing order, and the percentile 
corresponding to the confidence level considered is selected, e.g., the 80th percentile for a 
confidence level of 0.80 (α;<). Next (step 4 in Figure 7), the standard deviation across the forest 
is used to calculate confidence regions for the data points in the test set as follows (step 4 in 
Figure 1): 
 Equation	2:						>?@ABC6@D6	E6FB?@ = 	"G5 ± I"J − "G5 I = "G5 ± (67L ∗ 	9NO) 
 
Where "J is the jth instance in the test set, "G5 	and $J are the average and the standard deviation 
of the predicted activities for the jth instance across the forest, respectively, and αQRis the non-
conformity score for the selected confidence level.  
 
 
Figure 7. Steps for the generation of Inductive Conformal Predictors in the context of regression.   
Train one machine 
learning model
Calibration set (15%) Test set (15%) Training set (70%)
Calibration set point 
predictions and prediction errors
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Choosing an appropriate non-conformity measure is essential in regression to maximize 
efficiency, defined as the average size of the confidence regions. Svensson et al.40 
benchmarked the efficiency of the following 6 approaches to scale the errors in prediction in the 
non-conformity function (Equation 1) using RF models and 29 public bioactivity data sets: (i) 
standard deviation across the trees in the RF model, (ii) the interpercentile range (10th to 90th) of 
the predictions across the trees in the RF model, (iii) the predicted error generated by a 
separate model trained on compound descriptors and using the cross-validation residuals as the 
dependent variable, (iv) the distance in two-component Principal Component Analysis (PCA) 
space computed using compound descriptors to the center of all training data, (v) the average 
distance to the five nearest neighbours in two-dimensional incremental PCA, and (vi) t-SNE 
space. Although the 6 non-conformity functions generated well-calibrated confidence intervals, 
their efficiency varied considerably, showing that the natural exponential of the RF ensemble 
standard deviation led to the tightest intervals, with an average prediction range of 1.65 pIC50 
units; using the ensemble interpercentile range and a separate error model led to slightly worse 
performance. The exponential scaling sets the upper value for the list of non-conformity scores 
to be equal to the largest residual in the calibration set, as the exponential converts low $ to 
values close to unity40,63,81. Lapins et al74. included a smoothing factor to (i) make large intervals 
slightly smaller, thus mitigating the effect of potentially inaccurate, large $ values, and (ii) 
increase the size of very small intervals not reflecting the inherent uncertainty of bioactivity 
measurements85–87,91.  
 
A number of the Conformal Predictors reported in the literature applied to regression tasks use 
RF models as the underlying algorithm (Table 2), and employ the standard deviation across 
base learners to scale the residuals and compute non-conformity scores40,92 (Equation 1), a 
choice supported by comparative analysis of non-conformity measures40. RF models are widely 
used in Conformal Prediction because the generation of an ensemble comes at no extra 
computational cost15,32, the training can be parallelized, and the performance is stable across 
parameter values, thus requiring little parameter tuning. The variance across base learners (i.e., 
the bagged variance across the trees in RF models) conveys a predictive signal to quantify the 
uncertainty of individual predictions, as the average RMSE on the test set increases with the 
variance among predictions22,29. However, one should note that this numerical Pearson 
correlation between variance and prediction error is much weaker than the inflated correlation 
obtained by binning the test compounds on the basis of the predicted variance22,29,93, which in 
practice means that the size of the confidence regions calculated using non-conformity 
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measures based on the bagged variance will not be strongly correlated with the unsigned error 
in prediction. In other words, the average RMSE on the test set is correlated with the size of the 
confidence interval computed using Conformal Predictors because, on average (but not in every 
individual case) the larger the variance across the ensemble, the larger the predicted 
confidence region will be (Equation 2). Other studies have used a second machine learning 
model, termed error model, to predict errors in prediction to identify which predictions are less 
reliable in a similar manner as the standard deviation across the forest is used in RF-based 
conformal predictors (Equation 1). This is achieved by training a model on the same chemical 
descriptors used to train a point prediction model to predict the error in prediction during cross-
validation92 or for the calibration set instances32. In other cases other metrics are used as 
covariates31,94, or linear methods95. Overall, this approach has been shown to deliver less 
efficient Conformal Predictors as compared to those generated using the bagged variance when 
modelling QSAR data sets40. 
 
Inductive CP has been applied to diverse regression tasks (Table 2), including 
proteochemometric modelling of PARP inhibitors46 and the prediction of patterns of growth 
inhibition across cancer cell line panels92. However, most studies using CP for regression tasks 
have implemented CP modalities designed to use all available training data for learning, which 
we discuss in the next section. 
 
 
Conformal Prediction Using All Labelled Data for Learning  
 
A common disadvantage to all the CP modalities revisited so far is that not all data available for 
training are used for model fitting, as the calibration set needs to be kept aside to generate the 
list of non-conformity scores (Figures 2 and 4). However, it would be desirable to use all 
available data during training to increase the predictive power of the resulting models, in 
particular in cases where few data points are available for a given class or a particular region of 
the bioactivity range considered. Several CP modalities have been developed to date to solve 
this issue96,97. We here revisit the two most widely used in drug discovery in both regression and 
classification tasks (Table 2), namely Aggregated Conformal Prediction (ACP)98,99 and Cross 
Conformal Prediction (CCP)96. 
 
- Aggregated Conformal Prediction (ACP) 
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The ACP approach consists of generating a collection of usually 10-10043,56,80 Inductive 
Conformal Predictors (e.g., Inductive MCP), each of them trained on the same training data but 
with random assignments of training set instances to the proper training and calibration sets. 
Thus, the instances assigned to the calibration and proper training sets are different for each 
model, resulting in reduced variance for the predicted confidence regions, and increased 
efficiency98. In the case of classification, each model is applied to the test (or external) set 
instances, and the P values computed with each of these models are recorded for each 
instance (and for each class in the case of MCP). The final P value is calculated as e.g., the 
median P value and each instance is assigned to those classes for which the median P value is 
higher than the significance level. In the case of regression, the final confidence interval for 
each test set instance is also a function of the set of confidence intervals predicted by each of 
the set of models trained, such as half the difference between the median of the maximum and 
minimum predicted values61.  
 
ACP has been applied in diverse drug discovery tasks (Table 2), including Ames mutagenicity 
prediction67, multi-task learning using matrix factorization80, modelling of compound binding to 
the estrogen and androgen receptors54, and virtual screening of TRPV1 agonists100. Lindh et 
al.61 generated Aggregated Conformal Predictors to model the permeation rate through the 
human skin of 211 chemical compounds60. Whereas the predictive power did not increase with 
respect to previous models reported for the same data set, CP added the advantage of 
providing predictions as confidence regions, and using all available data for training, which was 
crucial in this particular case due to the limited size of the training data. ACP has also proved 
versatile to model highly imbalanced data sets. For instance, Svensson et al.70 modelled 12 
highly-imbalanced bioactivity data sets from PubChem using ACP and a cost-gain function 
taking into account screening costs and the gain of finding active hits. ACP was also shown to 
accurately model highly-imbalanced cytotoxicity data sets from PubChem62, with only 0.8% of 
cytotoxic compounds, showing an external validation set a sensitivity of 74% and a specificity of 
65% for the single-label predictions at a confidence level of 80%. Lastly, ACP has also been 
applied in two iterative screening studies, where Conformal Prediction followed molecular 
docking in order to prioritize compounds for experimental testing56,101. Overall ACP has been 
found to reduce the variance and increase the efficiency of the predicted confidence intervals, 
while also permitting the use of all available data for training.  
 
- Cross-Conformal Prediction (CCP) 
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In CCP the training data set is divided into k non-overlapping sets, in a similar manner as 
performed in k-fold cross validation. Next, k ICP models are trained, each time using a different 
set as calibration set, thus permitting the use of all labelled data for training. For each instance 
in the test set k P values are generated, whose e.g., mean value can be used as the output P 
value. The output P values are compared against the significance level to assign a class to the 
test instances (or classes in the case of Mondrian CCP). To date, Mondrian CCP has been 
mostly applied to model imbalanced bioactivity data sets (Table 2). Sun et al.57 reported SVM-
based classification Mondrian CCP models showing comparable performance to SVM models 
on external sets for 18 data sets from the ExCAPE database8 with active to inactive ratios in the 
1:10 to 1:1000 range. The Mondrian CCP models were well-calibrated for both the majority and 
the minority class. Notably, the authors reported higher efficiency for Mondrian CCP models 
using a non-conformity measure based on the distance to the SVM decision boundary as 
compared to a non-conformity measure based on the Tanimoto distance to the 5 nearest 
neighbours in the training data. Giblin et al.69 conducted one of the few studies where CP 
guided prospective validation experiments. Specifically, the authors built Mondrian CCP 
proteochemometric102 models using bioactivity data for 6,352 compounds across 31 
bromodomains (15,350 data points), which showed a maximum Matthew’s Correlation 
Coefficient of 0.83 on an external test set. 319 compound-target pairs were confirmed out of 
1,139 experimentally validated, where the selection included compounds with high and low 
confidence values and different bioactivity profiles against sets of bromodomains. In the context 
of regression, CCP has been applied to model compound lipophilicity on a large scale. Lapins et 
al.74 harnessed calculated logD values for 1,592,127 compounds extracted from ChEMBL 
version 23 to generate an SVM-based CCP using 10-fold cross validation. The errors in 
prediction were calculated as the median prediction midpoint +/- the median predicted interval 
size across the 10 models. The final model, which achieved median confidence intervals of ± 
0.39 and 0.60 log units at 80% and 90% confidence, respectively, was further applied to 
91,498,351 compounds extracted from the PubChem database. These predictions were made 
publicly available at https://cplogd.service.pharmb.io. Overall, these studies show the versatility 
of CCP prediction, which permits to obtain valid and efficient conformal predictors while using all 
available labelled data for training. 
 
 
Conformal Prediction Methods for Deep Learning 
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Deep learning is currently applied in many tasks of the drug discovery process, a trend that is 
only expected to rise in the next years103,104. The predictions output by deep learning 
classification models are overall well calibrated, or can be easily calibrated using e.g., Platt 
Scaling or Isotonic Regression105. Therefore, there is little benefit in using CP on top of deep 
learning models generated for classification tasks. However, in the case of regression deep 
learning models simply output point predictions, thus not providing information about the 
reliability of individual predictions directly. In addition to variational Bayesian inference 
methods20,21, CP has been applied to deep learning models to estimate reliable confidence 
intervals for individual predictions. The application of CP to regression networks was initially 
proposed by Papadopoulos et al.95. In drug discovery, the authors recently proposed two 
methods to obtain reliable confidence intervals for regression networks at minimal 
computational cost. The first approach, Deep Confidence63, harnesses the predictions 
generated by intermediate network states corresponding to the local minima visited during the 
training of a single network to build an ensemble of predictions. The variability across the 
ensemble can be used to scale the absolute errors in prediction in a similar way as performed 
using the bagged variance in the case of RF models. More recently, we proposed a second 
method, Test-Time Dropout Conformal Prediction81, that consists of training a network using 
dropout106. Next, the network is applied to compute N forward passes using dropout as well. As 
in the case of Deep Confidence, the variability across these forward passes is used to scale the 
absolute errors in prediction. Overall, it could be shown that both Deep Confidence and Test-
Time Dropout Conformal Prediction deliver well-calibrated predicted confidence intervals that, in 
addition, span a narrower range of values than those computed using RF-based models. 
 
Open-Source Implementations of Conformal Prediction 
 
The increased adoption of CP in early-stage drug discovery settings has fostered the 
implementation of several CP modalities in open-source software libraries in the R programming 
language and Python, which are widely used programming languages in medicinal chemistry 
applications107,108. The availability of predictive modelling packages in both R (e.g., caret109 or 
camb110) and Python (e.g., scikit-learn111 or PyTorch112) has facilitated the integration of existing 
computational drug discovery pipelines and CP56,110.  
 
The Python nonconformist package (http://donlnz.github.io/nonconformist/index.html) provides 
functionalities to generate Inductive and Aggregated Conformal Predictors for both regression 
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and classification tasks. CPSign113 (http://cpsign-docs.genettasoft.com/) is another Python 
implementation of CP for chemoinformatic tasks that uses SVM and Signature molecular 
descriptors. The R package conformal46 (https://github.com/isidroc/conformal) is an object-
oriented programming implementation of CP that provides S4 classes to construct classification 
and regression ICP models using Random Forest as the underlying algorithm. Similarly, the R 
package conformalClassification (https://cran.r-
project.org/web/packages/conformalClassification/index.html) permits to generate Transductive 
and Inductive Conformal Predictors based on RF models for classification tasks. The availability 
of well-documented and structured software will increase the reproducibility of published results, 
and allow for robust benchmarking studies of novel methods. Hence, we advocate for the 
publication of source code in future CP studies, in line with current recommendations in the 
modelling community114,115. 
 
Current Limitations of Conformal Prediction and Future Perspectives 
 
While Conformal Prediction, as described above, is able to assign confidence to predictions 
within a computationally efficient framework some areas of ongoing methodological research 
certainly remain. A major issue in CP applied to regression is the low efficiency of most CP 
models, which leads to the predicted confidence regions to span multiple e.g., pIC50 units. Such 
large intervals are not informative and thus hamper the practical usefulness of CP. Substantial 
efforts in the community have been invested in investigating and developing non-conformity 
functions to reduce the size of the predicted confidence regions40,63,90,116. However, future 
research will be needed to improve current non-conformity measures in order to, ultimately, 
generate errors in prediction comparable to the uncertainty of the data85–87. In classification 
settings, a common problem faced is the substantial increase of instances predicted to belong 
to multiple categories as the confidence level is increased32,78. This problem is analogous to the 
lack of efficiency of regression models. As in the regression case, the development of improved 
non-conformity measures57,80 will be needed to improve the efficiency of classification CP 
models. Another major shortcoming of the predicted confidence regions in the case of 
regression is the poor correlation between the absolute error in prediction (i.e., unsigned error) 
and the size of the confidence interval. This is due to the fact that error models used in non-
conformity measures e.g., the bagged variance, do not predict accurately the error in 
prediction89,94 . Thus, large confidence intervals are obtained for accurate predictions and vice 
versa. Using alternative methods to the bagged variance to compute nonconformity scores, 
such as quantitative metrics developed in the QSAR arena to estimate the applicability domain 
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of the models26, might alleviate this issue. Similarly, algorithms other than the most widely used 
to date (RF, SVM and neural networks; Table 2) might also be considered in drug discovery 
applications as alternative methods to generate more efficient Conformal Predictors80,90.  
 
Today, Mondrian CP modalities, including Mondrian ACP and CCP, have become the standard 
approach to model imbalanced data sets when using Conformal Prediction. However, also the 
data sets themselves which are used to model compound activity on a continuous scale are 
generally biased, which leads to an uneven coverage of the chemical space across the 
bioactivity range considered, and hence variable errors rates across it94. Therefore, the 
development of methods to handle the uneven distribution of datapoints across the bioactivity 
range considered in regression models would be useful to remove biases from models, and 
hence guarantee that the validity and efficiency of the predicted confidence intervals are even 
across the bioactivity range modelled, and not only across the entire bioactivity range.  
 
The integration of predictions generated by independent conformal predictors is a current area 
of intense research, similar to ensemble approaches in other domains. Toccaceli et al.117 
recently introduced a method to integrate ICP models trained on different underlying algorithms. 
Notably, the combined models outperformed base learners (linear SVM, Gradient Boosted 
Trees, and k-Nearest Neighbours) on an IDH1 bioactivity data set extracted from the ExCAPE 
database8. An alternative approach to integrate CP models, applicable to both classification and 
regression models, is Synergy CP97, which permits the aggregation of CP models trained in 
parallel on subsets of the training data into valid and efficient Conformal Predictors. Overall, 
these studies represent innovative solutions that will permit not only performance 
improvements, but also the exploitation for drug discovery of (proprietary) data dispersed across 
companies and institutions in distributed environments. 
 
As stated above, the validity of CP is only guaranteed if the randomness or exchangeability 
assumptions hold. This assumption is however not usually verified in practice, and it is only 
assumed that the training data and the molecules to which CP models are applied are drawn 
from the same distribution. It is of course unlikely that the chemical space covered in the training 
data of virtual screening models, even if these encompass thousands of molecules, is entirely 
representative of the entire chemical space already comprised in academic and commercial 
chemical libraries, or amenable to chemical synthesis. In fact, the authors recently showed 
using iterative virtual screening experiments that breaching the randomness assumption leads 
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to useless conformal predictors41. This issue is of particular relevance given that many of the CP 
reported to date are based on few hundred datapoints (Table 2). Therefore, further development 
of methods to determine to what extent the randomness or exchangeability assumptions hold 
would be useful in practice to make informed decisions on the applicability of the developed CP 
models on the basis of the difference between the training data and those molecules to which 
the models are applied. 
  
 33 
Acknowledgements 
This project has received funding from the European Union’s Framework Programme For 
Research and Innovation Horizon 2020 (2014-2020) under the Marie Curie Sklodowska-Curie 
Grant Agreement No. 703543 (I.C.C.).  
Conflicts of Interest 
The authors declare no conflict of interests. 
 
  
 34 
References 
1. Vayena, E., Blasimme, A. & Cohen, I. G. Machine learning in medicine: 
Addressing ethical challenges. PLOS Med. 15, e1002689 (2018). 
2. Segall, M. D. & Champness, E. J. The challenges of making decisions using 
uncertain data. J. Comput. Aided. Mol. Des. 29, 809–16 (2015). 
3. Hanser, T., Barber, C., Marchaland, J. F. & Werner, S. Applicability domain: 
towards a more formal definition. SAR QSAR Environ. Res. 27, 865–881 (2016). 
4. Tetko, I. V, Bruneau, P., Mewes, H.-W., Rohrer, D. C. & Poda, G. I. Can we 
estimate the accuracy of ADME-Tox predictions? Drug Discov. Today 11, 700–
707 (2006). 
5. Weaver, S. & Gleeson, M. P. The importance of the domain of applicability in 
QSAR modeling. J. Mol. Graph. Model. 26, 1315–1326 (2008). 
6. Toplak, M. et al. Assessment of Machine Learning Reliability Methods for 
Quantifying the Applicability Domain of QSAR Regression Models. J. Chem. Inf. 
Model. 54, 431–441 (2014). 
7. Netzeva, T. I. et al. Current Status of Methods for Defining the Applicability 
Domain of ( Quantitative ) Structure – Activity Relationships. 2, (2005). 
8. Sun, J. et al. ExCAPE-DB: an integrated large scale dataset facilitating Big Data 
analysis in chemogenomics. J. Cheminform. 9, 17 (2017). 
9. Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–
D954 (2017). 
10. Cherkasov, A. et al. QSAR modeling: where have you been? Where are you 
going to? J. Med. Chem. 57, 4977–5010 (2014). 
11. Lecun, Y., Bengio, Y. & Hinton, G. Deep learning. Nature 521, 436–444 (2015). 
12. Todeschini, R. & Consonni, V. Handbook of Molecular Descriptors. (2008). 
doi:10.1002/9783527613106 
13. Rivas-Perea, P. et al. Support Vector Machines for Regression: A Succinct 
Review of Large-Scale and Linear Programming Formulations. Int. J. 3, (2013). 
14. Cortes, C. & Vapnik, V. Support-Vector Networks. Mach. Learn. 20, 273–297 
(1995). 
15. Breiman, L. Random Forests. Mach. Learn. 45, 5–32 (2001). 
16. Obrezanova, O., Csányi, G., Gola, J. M. R. & Segall, M. D. Gaussian Processes: 
A Method for Automatic QSAR Modeling of ADME Properties. J. Chem. Inf. 
Model. 47, 1847–1857 (2007). 
17. Cortes-Ciriano, I. et al. Proteochemometric modeling in a Bayesian framework. J. 
Cheminf. 6, 35 (2014). 
18. Obrezanova, O. & Segall, M. D. Gaussian processes for classification: QSAR 
modeling of ADMET and target activity. J. Chem. Inf. Model. 50, 1053–1061 
(2010). 
19. Rasmussen, C. E. & Williams, C. K. I. Gaussian Processes for Machine Learning. 
(Mit Press, 2006). 
20. Zhang, Y. & Lee, A. A. Bayesian semi-supervised learning for uncertainty-
calibrated prediction of molecular properties and active learning. (2019). 
21. Gal, Y., Ghahramani, Z., Uk, Z. A. & Ghahramani, Z. Dropout as a Bayesian 
Approximation: Representing Model Uncertainty in Deep Learning. 2015, 
arXiv1506.02142 arXiv.org ePrint Arch. https//arxiv.org/abs/1506.02142 
 35 
(accessed Jul 10, 2018). (2015). 
22. Sheridan, R. P. Using Random Forest To Model the Domain Applicability of 
Another Random Forest Model. J. Chem. Inf. Model. 53, 2837–2850 (2013). 
23. Svetnik, V. et al. Random forest: a classification and regression tool for compound 
classification and QSAR modeling. J. Chem. Inf. Comp. Sci. 43, 1947–1958 
(2003). 
24. Berenger, F. & Yamanishi, Y. A Distance-Based Boolean Applicability Domain for 
Classification of High Throughput Screening Data. J. Chem. Inf. Model. 59, 463–
476 (2019). 
25. Liu, R. & Wallqvist, A. Molecular Similarity-Based Domain Applicability Metric 
Efficiently Identifies Out-of-Domain Compounds. 59, 181–189 (2019). 
26. Netzeva, T. I. et al. Current status of methods for defining the applicability domain 
of (quantitative) structure-activity relationships. The report and recommendations 
of ECVAM Workshop 52. Altern. Lab. Anim. 33, 155–173 (2005). 
27. Sushko, I. et al. Applicability domain for in silico models to achieve accuracy of 
experimental measurements. J. Chemom. 24, 202–208 (2010). 
28. Sahigara, F. Defining the Applicability Domain of QSAR models : An overview. 
Mol. Descriptors. Free online Resour. 1–6 (2007). 
29. Wood, D. J., Carlsson, L., Eklund, M., Norinder, U. & Stålring, J. QSAR with 
experimental and predictive distributions: an information theoretic approach for 
assessing model quality. J. Comput. Aided Mol. Des. 27, 203–219 (2013). 
30. Schroeter, T. S. et al. Estimating the domain of applicability for machine learning 
QSAR models: a study on aqueous solubility of drug discovery molecules. J. 
Comput. Mol. Des. 21, 485–498 (2007). 
31. Sheridan, R. P. The Relative Importance of Domain Applicability Metrics for 
Estimating Prediction Errors in QSAR Varies with Training Set Diversity. J. Chem. 
Inf. Model. 55, 1098–1107 (2015). 
32. Norinder, U. et al. Introducing Conformal Prediction in Predictive Modeling. A 
Transparent and Flexible Alternative To Applicability Domain Determination. J. 
Chem. Inf. Model. 54, 1596–1603 (2014). 
33. Schwaighofer, A. et al. Accurate solubility prediction with error bars for 
electrolytes: a machine learning approach. J. Chem. Inf. Model. 47, 407–424 
(2007). 
34. Liu, R., Glover, K. P., Feasel, M. G. & Wallqvist, A. General Approach to Estimate 
Error Bars for Quantitative Structure–Activity Relationship Predictions of 
Molecular Activity. J. Chem. Inf. Model. 58, 1561–1575 (2018). 
35. Cortes-Ciriano, I., Murrell, D. S., van Westen, G. J. P., Bender, A. & Malliavin, T. 
Prediction of the Potency of Mammalian Cyclooxygenase Inhibitors with 
Ensemble Proteochemometric Modeling. J. Cheminf. 7, 1 (2014). 
36. Vovk, V., Gammerman, A. & Shafer, G. Algorithmic learning in a random world. 
(Springer, 2005). 
37. Shafer, G. & Vovk, V. A Tutorial on Conformal Prediction. J. Mach. Learn. Res. 9, 
371–421 (2008). 
38. Vovk, V., Fedorova, V., Nouretdinov, I. & Gammerman, A. Criteria of efficiency for 
conformal prediction. in Lecture Notes in Computer Science (including subseries 
Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) 9653, 
 36 
23–39 (2016). 
39. Norinder, U., Carlsson, L., Boyer, S. & Eklund, M. Introducing conformal 
prediction in predictive modeling for regulatory purposes. A transparent and 
flexible alternative to applicability domain determination. Regul. Toxicol. 
Pharmacol. 71, 279–284 (2015). 
40. Svensson, F. et al. Conformal Regression for Quantitative Structure–Activity 
Relationship Modeling—Quantifying Prediction Uncertainty. J. Chem. Inf. Model. 
58, 1132–1140 (2018). 
41. Cortes-Ciriano, I., Firth, N. C., Bender, A. & Watson, O. Discovering highly potent 
molecules from an initial set of inactives using iterative screening. J. Chem. Inf. 
Model. 58, 2000–2014 (2018). 
42. Johansson, U., Linusson, H., Löfström, T. & Boström, H. Interpretable regression 
trees using conformal prediction. Expert Syst. Appl. 97, 394–404 (2018). 
43. Lampa, S. et al. Predicting Off-Target Binding Profiles With Confidence Using 
Conformal Prediction. Front. Pharmacol. 9, 1256 (2018). 
44. Eklund, M., Norinder, U., Boyer, S. & Carlsson, L. The application of conformal 
prediction to the drug discovery process. Ann. Math. Artif. Intell. 74, 117–132 
(2015). 
45. Wahlberg, E. et al. Family-wide chemical profiling and structural analysis of PARP 
and tankyrase inhibitors. Nat. Biotechnol. 30, 283–288 (2012). 
46. Cortés-Ciriano, I., Bender, A. & Malliavin, T. Prediction of PARP Inhibition with 
Proteochemometric Modelling and Conformal Prediction. Mol. Inform. 34, 357–
366 (2015). 
47. Fjodorova, N., Vračko, M., Novič, M., Roncaglioni, A. & Benfenati, E. New public 
QSAR model for carcinogenicity. Chem. Cent. J. 4, S3 (2010). 
48. Ferrari, T. & Gini, G. An open source multistep model to predict mutagenicity from 
statistical analysis and relevant structural alerts. Chem. Cent. J. 4, S2 (2010). 
49. Ahlberg, E., Spjuth, O., Hasselgren, C. & Carlsson, L. Interpretation of Conformal 
Prediction Classification Models. in 323–334 (Springer, Cham, 2015). 
doi:10.1007/978-3-319-17091-6_27 
50. Cortés-Ciriano, I. et al. Improved large-scale prediction of growth inhibition 
patterns using the NCI60 cancer cell line panel. Bioinformatics 32, 85–95 (2016). 
51. Cortes-Ciriano, I. et al. Cancer Cell Line Profiler (CCLP): a webserver for the 
prediction of compound activity across the NCI60 panel. bioRxiv 105478 (2017). 
doi:10.1101/105478 
52. Kuiper, G. G. J. M. et al. Comparison of the Ligand Binding Specificity and 
Transcript Tissue Distribution of Estrogen Receptors α and β. Endocrinology 138, 
863–870 (1997). 
53. Taha, M. O., Tarairah, M., Zalloum, H. & Abu-Sheikha, G. Pharmacophore and 
QSAR modeling of estrogen receptor β ligands and subsequent validation and in 
silico search for new hits. J. Mol. Graph. Model. 28, 383–400 (2010). 
54. Norinder, U., Rybacka, A. & Andersson, P. L. Conformal prediction to define 
applicability domain – A case study on predicting ER and AR binding. SAR QSAR 
Environ. Res. 27, 303–316 (2016). 
55. Mysinger, M. M., Carchia, M., Irwin, J. J. & Shoichet, B. K. Directory of useful 
decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. 
 37 
J. Med. Chem. 55, 6582–6594 (2012). 
56. Svensson, F., Norinder, U. & Bender, A. Improving Screening Efficiency through 
Iterative Screening Using Docking and Conformal Prediction. J. Chem. Inf. Model. 
57, 439–444 (2017). 
57. Sun, J. et al. Applying Mondrian Cross-Conformal Prediction To Estimate 
Prediction Confidence on Large Imbalanced Bioactivity Data Sets. J. Chem. Inf. 
Model. 57, 1591–1598 (2017). 
58. Hansen, K. et al. Benchmark Data Set for in Silico Prediction of Ames 
Mutagenicity. J. Chem. Inf. Model. 49, 2077–2081 (2009). 
59. Norinder, U. & Boyer, S. Binary classification of imbalanced datasets using 
conformal prediction. J. Mol. Graph. Model. 72, 256–265 (2017). 
60. Baba, H., Takahara, J. & Mamitsuka, H. In Silico Predictions of Human Skin 
Permeability using Nonlinear Quantitative Structure–Property Relationship 
Models. Pharm. Res. 32, 2360–2371 (2015). 
61. Lindh, M., Karlén, A. & Norinder, U. Predicting the Rate of Skin Penetration Using 
an Aggregated Conformal Prediction Framework. Mol. Pharm. 14, 1571–1576 
(2017). 
62. Svensson, F., Norinder, U. & Bender, A. Modelling compound cytotoxicity using 
conformal prediction and PubChem HTS data. Toxicol. Res. (Camb). 6, 73–80 
(2017). 
63. Cortés-Ciriano, I., Bender, A., Cortes-Ciriano, I. & Bender, A. Deep Confidence: A 
Computationally Efficient Framework for Calculating Reliable Prediction Errors for 
Deep Neural Networks. J. Chem. Inf. Model. 59, 1269–1281 (2019). 
64. Huang, G. et al. Snapshot Ensembles: Train 1, get M for free. 2017, 
arXiv1704.00109 arXiv.org ePrint Arch. https//arxiv.org/abs/1704.00109 
(accessed Jul 10, 2018). 
65. Norinder, U. et al. Predicting Aromatic Amine Mutagenicity with Confidence: A 
Case Study Using Conformal Prediction. Biomolecules 8, 85 (2018). 
66. Honma, M. et al. Improvement of quantitative structure–activity relationship 
(QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR 
International Challenge Project. Mutagenesis 34, 3–16 (2019). 
67. Norinder, U., Ahlberg, E. & Carlsson, L. Predicting Ames Mutagenicity Using 
Conformal Prediction in the Ames/QSAR International Challenge Project. 
Mutagenesis (2018). doi:10.1093/mutage/gey038 
68. Norinder, U., Mucs, D., Pipping, T. & Forsby, A. Creating an efficient screening 
model for TRPV1 agonists using conformal prediction. Comput. Toxicol. 6, 9–15 
(2018). 
69. Giblin, K. A., Hughes, S. J., Boyd, H., Hansson, P. & Bender, A. Prospectively 
Validated Proteochemometric Models for the Prediction of Small-Molecule Binding 
to Bromodomain Proteins. J. Chem. Inf. Model. 58, 1870–1888 (2018). 
70. Svensson, F., Afzal, A. M., Norinder, U. & Bender, A. Maximizing gain in high-
throughput screening using conformal prediction. J. Cheminform. 10, 7 (2018). 
71. Johansson, H., Lindstedt, M., Albrekt, A.-S. & Borrebaeck, C. A. A genomic 
biomarker signature can predict skin sensitizers using a cell-based in vitro 
alternative to animal tests. BMC Genomics 12, 399 (2011). 
72. Forreryd, A., Norinder, U., Lindberg, T. & Lindstedt, M. Predicting skin sensitizers 
 38 
with confidence — Using conformal prediction to determine applicability domain of 
GARD. Toxicol. Vitr. 48, 179–187 (2018). 
73. Ji, C., Svensson, F., Zoufir, A. & Bender, A. eMolTox: prediction of molecular 
toxicity with confidence. Bioinformatics 34, 2508–2509 (2018). 
74. Lapins, M. et al. A confidence predictor for logD using conformal regression and a 
support-vector machine. J. Cheminform. 10, 17 (2018). 
75. Dua, Dheeru and Graff, C. UCI Machine Learning Repository. University of 
California, Irvine, School of Information and Computer Sciences (2017). Available 
at: http://archive.ics.uci.edu/ml. (Accessed: 1st July 2019) 
76. Spjuth, O., Carlsson, L. & Gauraha, N. Aggregating Predictions on Multiple Non-
disclosed Datasets using Conformal Prediction. (2018). 
77. Gauraha, N., Carlsson, L. & Spjuth, O. Conformal Prediction in Learning Under 
Privileged Information Paradigm with Applications in Drug Discovery. (2018). 
78. Bosc, N. et al. Large scale comparison of QSAR and conformal prediction 
methods and their applications in drug discovery. J. Cheminform. 11, 4 (2019). 
79. de la Vega de León, A., Chen, B. & Gillet, V. J. Effect of missing data on multitask 
prediction methods. J. Cheminform. 10, 26 (2018). 
80. Norinder, U. & Svensson, F. Multitask Modeling with Confidence Using Matrix 
Factorization and Conformal Prediction. J. Chem. Inf. Model. acs.jcim.9b00027 
(2019). doi:10.1021/acs.jcim.9b00027 
81. Cortés-Ciriano, I. & Bender, A. Reliable Prediction Errors for Deep Neural 
Networks Using Test-Time Dropout. J. Chem. Inf. Model. 59, 3330–3339 (2019). 
82. Eklund, M., Norinder, U., Boyer, S. & Carlsson, L. Benchmarking Variable 
Selection in QSAR. Mol. Inf. 31, 173–179 (2012). 
83. Cortés-Ciriano, I. & Bender, A. KekuleScope: prediction of cancer cell line 
sensitivity and compound potency using convolutional neural networks trained on 
compound images. J. Cheminform. 11, 41 (2019). 
84. Vovk, V., Hoi, S. C. H. & Buntine, W. Conditional validity of inductive conformal 
predictors. Mach Learn 92, 349–376 (Springer US, 2013). 
85. Kramer, C., Kalliokoski, T., Gedeck, P. & Vulpetti, A. The experimental uncertainty 
of heterogeneous public K(i) data. J. Med. Chem. 55, 5165–5173 (2012). 
86. Cortés-Ciriano, I. & Bender, A. How consistent are publicly reported cytotoxicity 
data? Large-scale statistical analysis of the concordance of public independent 
cytotoxicity measurements. ChemMedChem 11, 57–71 (2015). 
87. Kalliokoski, T., Kramer, C., Vulpetti, A. & Gedeck, P. Comparability of mixed IC₅₀ 
data - a statistical analysis. PLoS One 8, e61007 (2013). 
88. Roberts, G., Myatt, G. J., Johnson, W. P., Cross, K. P. & Blower, P. E. 
LeadScope : Software for Exploring Large Sets of Screening Data. J. Chem. Inf. 
Comput. Sci. 40, 1302–1314 (2000). 
89. Beck, B., Breindl, A. & Clark, T. QM/NN QSPR Models with Error Estimation: 
Vapor Pressure and LogP. J. Chem. Inf. Comput. Sci. 40, 1046–1051 (2000). 
90. Papadopoulos, H., Vovk, V. & Gammerman, A. Regression conformal prediction 
with nearest neighbours. J. Artif. Intell. Res. 40, 815–840 (2011). 
91. Kalliokoski, T., Kramer, C. & Vulpetti, A. Quality Issues with Public Domain 
Chemogenomics Data. Mol. Inform. 32, 898–905 (2013). 
92. Cortés-Ciriano, I. et al. Improved large-scale prediction of growth inhibition 
 39 
patterns on the NCI60 cancer cell-line panel. Bioinformatics 32, 85–95 (2016). 
93. Wainer, H., Gessaroli, M. & Verdi, M. Visual Revelations. CHANCE 19, 49–52 
(2006). 
94. Sheridan, R. P. Three useful dimensions for domain applicability in QSAR models 
using random forest. J. Chem. Inf. Model. 52, 814–823 (2012). 
95. Papadopoulos, H. & Haralambous, H. Reliable prediction intervals with regression 
neural networks. Neural Networks 24, 842–851 (2011). 
96. Vovk, V. Cross-conformal predictors. Ann. Math. Artif. Intell. 74, 9–28 (2015). 
97. Gauraha, N. & Spjuth, O. Synergy Conformal Prediction. (2018). 
98. Carlsson, L., Eklund, M. & Norinder, U. Aggregated Conformal Prediction. in 231–
240 (Springer, Berlin, Heidelberg, 2014). doi:10.1007/978-3-662-44722-2_25 
99. Linusson, H. et al. On the Calibration of Aggregated Conformal Predictors. Proc. 
Mach. Learn. Res. 60, 1–20 (2017). 
100. Ha, T.-H. et al. TRPV1 antagonist with high analgesic efficacy: 2-Thio pyridine C-
region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides. 
Bioorg. Med. Chem. 21, 6657–6664 (2013). 
101. Ahmed, L. et al. Efficient iterative virtual screening with Apache Spark and 
conformal prediction. J. Cheminform. 10, 8 (2018). 
102. Cortes-Ciriano, I. et al. Polypharmacology Modelling Using Proteochemometrics: 
Recent Developments and Future Prospects. Med. Chem. Comm. 6, 24 (2015). 
103. Carpenter, K. A., Cohen, D. S., Jarrell, J. T. & Huang, X. Deep learning and virtual 
drug screening. Future Med. Chem. 10, 2557–2567 (2018). 
104. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M. & Blaschke, T. The rise of deep 
learning in drug discovery. Drug Discov. Today 23, 1241–1250 (2018). 
105. Niculescu-Mizil, A. & Caruana, R. Predicting good probabilities with supervised 
learning. in Proceedings of the 22nd international conference on Machine learning  
- ICML ’05 625–632 (ACM Press, 2005). doi:10.1145/1102351.1102430 
106. Srivastava, N., Hinton, G., Krizhevsky, A. & Salakhutdinov, R. Dropout: A Simple 
Way to Prevent Neural Networks from Overfitting. J. Mach. Learn. Res. 15, 1929–
1958 (2014). 
107. Nowotka, M., Papadatos, G., Davies, M., Dedman, N. & Hersey, A. Want Drugs? 
Use Python. 2016, arXiv1607.00378 arXiv.org ePrint Arch. 
https//arxiv.org/abs/1607.00378 (accessed Jul 10, 2018). 
108. Mente, S. & Kuhn, M. The use of the R language for medicinal chemistry 
applications. Curr. Top. Med. Chem. 12, 1957–1964 (2012). 
109. Kuhn, M. Building Predictive Models in R Using the caret Package. J. Stat. Softw. 
28, 1–26 (2008). 
110. Murrell, D. S. et al. Chemically Aware Model Builder (camb): an R package for 
property and bioactivity modelling of small molecules. J. Cheminform. 7, 45 
(2015). 
111. Pedregosa, F. et al. Scikit-learn: Machine Learning in Python. J. Mach. Learn. 
Res. 12, 2825–2830 (2011). 
112. Paszke, A. et al. Automatic differentiation in PyTorch. in Advances in Neural 
Information Processing Systems 30 1–4 (2017). 
113. Arvidsson, S. CPSign Documentation — CPSign 0.7.8 documentation. (2016). 
114. Walters, W. P. Modeling, informatics, and the quest for reproducibility. J. Chem. 
 40 
Inf. Model. 53, 1529–1530 (2013). 
115. Landrum, G. A. & Stiefl, N. Is that a scientific publication or an advertisement? 
Reproducibility, source code and data in the computational chemistry literature. 
Future Med. Chem. 4, 1885–1887 (2012). 
116. Normalized Nonconformity Measures for Regression Conformal Prediction. 
(Proceedings of the IASTED international conference on artificial intelligence and 
applications, AIA. ACTA Press, 2008). 
117. Toccaceli, P. & Gammerman, A. Combination of inductive mondrian conformal 
predictors. Mach. Learn. 108, 489–510 (2019). 
 
